Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 4, pp. 317-324
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancers (2021) Vol. 13, Iss. 3, pp. 558-558
Open Access | Times Cited: 230
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 56
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 4, pp. 343-350
Closed Access | Times Cited: 101
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100354-100354
Open Access | Times Cited: 88
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100335-100335
Open Access | Times Cited: 80
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100337-100337
Open Access | Times Cited: 76
Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach
Felix Krenzien, Nora Nevermann, Alina Krombholz, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 362-362
Open Access | Times Cited: 54
Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
Samantha M. Ruff, Timothy M. Pawlik
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 9
Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges
Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, et al.
Current Oncology (2021) Vol. 28, Iss. 5, pp. 3393-3402
Open Access | Times Cited: 46
Patient-Derived Organoids of Cholangiocarcinoma
Christopher Maier, Lei Zhu, Lahiri Kanth Nanduri, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8675-8675
Open Access | Times Cited: 44
The epidemiological trends of biliary tract cancers in the United States of America
Jiang Yong, Liyong Jiang, Feiyu Li, et al.
BMC Gastroenterology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 32
Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI
Jelena Djokić Kovač, Aleksandra Janković, Aleksandra Đikić-Rom, et al.
Current Oncology (2022) Vol. 29, Iss. 2, pp. 698-723
Open Access | Times Cited: 28
Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Jiajia Du, Xing Lv, Zunyi Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use
Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 4, pp. 396-404
Open Access | Times Cited: 18
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
Recent 5‑year trends in biliary tract cancer survival rates: An analytical big data survey
Ji Yoon Lee, Ju Won Kim
Medicine International (2025) Vol. 5, Iss. 2
Closed Access
Site-specific metastases of gallbladder adenocarcinoma and their prognostic value for survival: a SEER-based study
Yingnan Yang, Zhuolong Tu, Chentao Ye, et al.
BMC Surgery (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 28
In search of novel inhibitors of anti-cancer drug target fibroblast growth factor receptors: Insights from virtual screening, molecular docking, and molecular dynamics
A. M. U. B. Mahfuz, Md. Arif Khan, Suvro Biswas, et al.
Arabian Journal of Chemistry (2022) Vol. 15, Iss. 7, pp. 103882-103882
Open Access | Times Cited: 19
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100356-100356
Open Access | Times Cited: 25
Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma
Fanli Zeng, Jing-fang Chen
Technology in Cancer Research & Treatment (2021) Vol. 20
Open Access | Times Cited: 25
Quality of Life and Symptom Management in Advanced Biliary Tract Cancers
Lindsay Hunter, Heloisa P. Soares
Cancers (2021) Vol. 13, Iss. 20, pp. 5074-5074
Open Access | Times Cited: 23
FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?
Paulina Chmiel, Katarzyna Gęca, Karol Rawicz‐Pruszyński, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3929-3929
Open Access | Times Cited: 18
Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology
Maurizio Capuozzo, Mariachiara Santorsola, Loris Landi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15124-15124
Open Access | Times Cited: 16
Synthesis and clinical application of new drugs approved by FDA in 2022
Jingyi Zhang, Yatao Wang, Lu Sun, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 9
Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma
Preawwalee Wintachai, Jing Quan Lim, Anchalee Techasen, et al.
Diagnostics (2021) Vol. 11, Iss. 6, pp. 999-999
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top